What Imperative Care does

Imperative Care, Inc. is a Campbell, California-based commercial-stage medical technology company founded in 2015 that develops and markets thrombectomy devices for ischemic stroke, pulmonary embolism, venous thromboembolism, and peripheral vascular disease. The company's Stroke Portfolio centers on the Zoom Stroke System, which integrates Zoom Intracranial Access, Zoom Aspiration Catheters, and Continuous Dual Aspiration (CDAT) technology for fast and effective clot removal from access through reperfusion, with multi-center real-world data reporting a median procedure time of 17 minutes using ADAPT 2.0 across 124 patients. The Vascular Portfolio consists of the Symphony Thrombectomy System, which received FDA clearance in August 2025 for treating acute pulmonary embolism and has treated over 500 PE patients commercially, and the Prodigy Thrombectomy System for acute limb ischemia, the latter built on the 2021 acquisition of Truvic Medical. The company is also developing the Telos endovascular robotic platform to bring precision, standardization, and remote access to thrombectomy procedures, though it is not yet approved for sale.

Imperative Care generates revenue through direct hardware sales of FDA-cleared thrombectomy systems to hospitals, stroke centers, interventional neuroradiology suites, pulmonary embolism treatment centers, and vascular surgery departments across the United States, supported by an enterprise field sales motion targeting interventional cardiologists, neuroradiologists, and vascular surgeons. The company invests heavily in clinical evidence generation, including the SYMPHONY-PE trial (109 intermediate-risk PE patients with favorable safety profile and no device-related serious adverse events) and the CLEAR-IT observational study enrolling up to 750 patients across up to 50 U.S. sites, and disseminates findings through peer-reviewed journals such as Circulation: Cardiovascular Interventions and at medical conferences such as the Society of Vascular and Interventional Neurology Annual Meeting.

The company has raised approximately $659 million in total funding across multiple rounds, including a $260 million Series D led by D1 Capital Partners in July 2021, a $150 million Series E led by Ally Bridge Group in July 2024, and an oversubscribed $100 million convertible note financing in March 2026 co-led by Elevage Medical Technologies and Perceptive Advisors with participation from Bain Capital Life Sciences, Catalio Capital Management, Ally Bridge Group, Brown Advisory, and Longaeva Partners. Imperative Care is a privately held company with 251-500 employees, operating through subsidiaries including Truvic Medical, with leadership including Chairman and CEO Farhad Khosravi, CFO Matthew Garrett, CTO Yi Yang, CCO Jay Martin, and founder Nick Hopkins.

Name

Imperative Care

Legal name

Imperative Care, Inc.

Website

https://imperativecare.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Imperative Care is a commercial-stage medical technology company developing FDA-cleared thrombectomy devices (Zoom Stroke System, Symphony, Prodigy) for hospitals and interventional centers treating ischemic stroke, pulmonary embolism, and acute limb ischemia, with a robotic platform (Telos) in development.

Ownership category

akta.pro rank

Product category

Neurovascular and Vascular Thrombectomy Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Thrombectomy medical devices
• Neurovascular intervention systems
• Ischemic stroke treatment
• Pulmonary embolism devices
• Endovascular robotic platform

Headquarters

HQ city

Campbell

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others

Revenue model

1. Medical Device Sales: Imperative Care generates revenue through the sale of its thrombectomy medical devices and systems to hospitals and healthcare providers. The company is a commercial-stage medtech with multiple FDA-cleared products including the Zoom Stroke System, Symphony Thrombectomy System, and Prodigy Thrombectomy System. Revenue is derived from direct hospital procurement and clinical adoption of its stroke and vascular thrombectomy portfolios.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Imperative Care develops and commercializes FDA-cleared thrombectomy medical devices for ischemic stroke, venous thromboembolism/pulmonary embolism, and acute limb ischemia. Its commercial portfolio includes the Zoom Stroke System (Zoom Aspiration Catheters, Zoom Intracranial Access, and CDAT technology), the Symphony Thrombectomy System (FDA-cleared August 2025), and the Prodigy Thrombectomy System, with the Telos endovascular robotic platform under development.

Product overview

Imperative Care is a medical technology company with a dual-portfolio approach: a Stroke Portfolio centered on the Zoom Stroke System (including Zoom Intracranial Access, Zoom Aspiration Catheters, and CDAT technology) for ischemic stroke treatment, and a Vascular Portfolio featuring the Symphony Thrombectomy System for venous thromboembolism/pulmonary embolism and the Prodigy Thrombectomy System for acute limb ischemia. The company is also developing the Telos robotic platform for endovascular procedures. In 2021, Imperative Care acquired Truvic Medical to enhance its peripheral vascular disease treatment capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Zoom Stroke System: Complete system for fast and effective clot removal in ischemic stroke patients - from access through reperfusion.
• Symphony Thrombectomy System
• Prodigy Thrombectomy System
• Telos Robotic Platform

Products and services

• Zoom Stroke System A complete stroke treatment system from access through reperfusion for fast and effective clot removal in a wide range of vessels for patients with ischemic stroke, intended for hospitals, stroke centers, and interventional neuroradiology suites.
• Symphony Thrombectomy System Aspiration-based thrombectomy system for the treatment of venous thromboembolism including pulmonary embolism in intermediate-risk PE patients, intended for cardiovascular and pulmonary care centers.
• Prodigy Thrombectomy System Thrombectomy system for treatment of acute limb ischemia and peripheral arterial thromboembolism, intended for vascular surgery and interventional radiology departments.

Quantifiable outcome

• Early mechanical thrombectomy within 12 hours of diagnosis for intermediate-risk PE patients showed mean pulmonary artery pressure reduction of 8.6 vs 5.8 for late treatment group (p=0.006)
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Truvic MedicalcoreStrategic or Co-development Partner · 1 July 2021Truvic Medical, a peripheral thrombectomy innovator, was acquired by Imperative Care in July 2021 to form a strategic network of subsidiaries focused on vascular interventions. Truvic operates as a subsidiary of Imperative Care advancing vascular intervention products including the Prodigy Thrombectomy System.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Penumbra: Penumbra is the closest direct competitor, with the Penumbra System aspiration catheters and JET family of aspiration thrombectomy devices targeting ischemic stroke, and the Indigo System for peripheral and pulmonary embolism thrombectomy — directly overlapping with both the Zoom and Symphony/Prodigy franchises.
• Stryker (Neurovascular): Stryker's Neurovascular division (acquired via Concentric Medical) markets the Trevo retriever and other stroke intervention devices; combined with its acquisition of Inari Medical, Stryker competes directly with Imperative Care across stroke and venous thromboembolism thrombectomy.
• Johnson & Johnson (Cerenovus): Cerenovus (J&J's neurovascular business) markets the EmboTrap and CERENOVUS stroke thrombectomy solutions, directly competing with the Zoom Stroke System in the same hospital accounts.
• AngioDynamics: AngioDynamics markets the AlphaVac mechanical thrombectomy system for pulmonary embolism and venous thromboembolism, directly competing with Symphony in the same PE indication.
• Inari Medical: Inari Medical (acquired by Stryker) developed the FlowTriever system for pulmonary embolism and the ClotTriever for peripheral venous thromboembolism — direct competitors to Symphony and Prodigy in the venous and PE thrombectomy space.
• Teleflex: Teleflex (via its Vascular Solutions / Arrow portfolio) markets the Mermaid and other peripheral thrombectomy tools, partially overlapping with Prodigy in peripheral arterial disease treatment.

Broad incumbents

• Medtronic: Medtronic's Neurovascular portfolio (Solitaire, React, Riptide aspiration) competes in ischemic stroke thrombectomy, while its broader cardiovascular franchise overlaps with vascular indications served by Symphony and Prodigy.
• Boston Scientific: Boston Scientific's peripheral intervention portfolio (AngioJet, thrombectomy catheters) overlaps with Prodigy in peripheral arterial/venous thrombectomy, and its broader interventional franchise competes for hospital budgets in the same procedure suites.
• Edwards Lifesciences: Edwards is a major cardiovascular medical device incumbent with growing presence in structural heart and critical care; its scale and hospital relationships create competitive pressure across the vascular thrombectomy purchasing environment.

Regional players

• Terumo: Terumo markets interventional and vascular access products (including aspiration and thrombectomy tools) primarily in Japan and Asia-Pacific, with overlapping technology that may compete with Imperative Care in international expansion scenarios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/imperative_care
• YouTubeyoutube.com/@ImperativeCare
• LinkedInlinkedin.com/company/imperativecare

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imperative Care